Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers

Blood Cancer Journal 2026 Open access

Read full text
Authors: J E Wiedmeier-Nutor, H E Kosiorek, M Arribas, H Simmons, A Jacob, S S Bhattu, R Fonseca, L Bruins, G Ahmann, U Yadav, Saurabh Chhabra, P L Bergsagel
+1 more R Fonseca
DOI: 10.1038/s41408-026-01508-9
Cited by: 1
References: 12

Abstract

Minimal residual disease (MRD) assessment is an important component of response evaluation and risk stratification in multiple myeloma (MM) [ 1 , 2 ]. The need for frequent bone marrow (BM) biopsy specimens has limitations, including procedural burden. Peripheral blood (PB) based approaches provide a less invasive and feasible approach for disease monitoring, including cases of heterogenous bone marrow involvement or extramedullary disease (EMD).

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research

Publication details

Journal / source
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
30 April 2026
Language
EN